SCHEMBL2470375

SCHEMBL2470375

Cc1ccccc1CCNC(=O)C1(c2ccccc2)CCN(C(=O)CCc2ccc(F)cc2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM5 P08912 1/20 0.49
CHRM3 P20309 1/20 0.49
GFER P55789 1/20 0.46
OPRL1 P41146 2/20 0.43
TAAR1 Q96RJ0 1/20 0.43
EPHX2 P34913 1/20 0.43
GPR183 P32249 1/20 0.42
USP19 O94966 1/20 0.42
PLAAT3 P53816 1/20 0.41
PLAAT5 Q96KN8 1/20 0.41
PLAAT2 Q9NWW9 1/20 0.41
PLAAT4 Q9UL19 1/20 0.41
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
NPC1 O15118 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
CCR3 P51677 1/20 0.40
ADRA1D P25100 1/20 0.40
ADRA1A P35348 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13183026 0.92 GFER (0.44) CHRM5CHRM3GFERTAAR1EPHX2
SCHEMBL2470510 0.91 CHRM5 (0.46) CHRM5CHRM3GFEROPRL1TAAR1
SCHEMBL2497408 0.90 CHRM5 (0.51) CHRM5CHRM3GFEROPRL1TAAR1
SCHEMBL2468618 0.89 CHRM5 (0.54) CHRM5CHRM3GFEROPRL1TAAR1
SCHEMBL2472379 0.89 CHRM5 (0.55) CHRM5CHRM3GFERTAAR1KMT2A
SCHEMBL2492390 0.88 CHRM5 (0.51) CHRM5CHRM3GFEROPRL1TAAR1
SCHEMBL2517627 0.87 CHRM5 (0.54) CHRM5CHRM3GFEROPRL1TAAR1
SCHEMBL14312643 0.85 GFER (0.43) GFERTAAR1EPHX2GPR183USP19
SCHEMBL2471734 0.85 EPHX2 (0.53) CHRM5CHRM3GFERTAAR1EPHX2
SCHEMBL2472649 0.85 CHRM5 (0.52) CHRM5CHRM3GFEROPRL1TAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2371366-A1 Heterocyclo inhibitors of potassium channel function Bristol-Myers Squibb Company (US) 2011-10-05 EP disclosed
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY 2009-12-17 US disclosed
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY 2009-12-17 US disclosed
US-7582654-B2 Heterocyclo inhibitors of potassium channel function BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-01 US disclosed
US-7582654-B2 Heterocyclo inhibitors of potassium channel function BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION KCNJ2, KCNH2, KCNQ5 CHRM5 676/4885CHRM3 1015/4885GFER 1562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.